GHRP-6 (Growth Hormone Releasing Peptide-6)
Overview
GHRP-6 is a synthetic hexapeptide ghrelin-receptor agonist and the prototypical growth-hormone-releasing peptide. First described in the 1980s, it was the peptide that established the GHRP class and remains a common historical benchmark. It is a strong GH secretagogue but also raises appetite and prolactin more than the newer, more selective peptides. It is a research compound.
Chemical Profile
| Property | Value |
|---|---|
| CAS number | 87616-84-0 |
| Class | Hexapeptide GHSR-1a agonist (first-generation GHRP) |
| Amino-acid sequence | H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ |
| Molecular formula | C₄₆H₅₆N₁₂O₆ |
| Molecular weight | 873.01 g/mol |
| Purity (HPLC) | ≥ 98% |
| Appearance | White to off-white lyophilized powder |
- Class
- Hexapeptide GHSR-1a agonist
- First described
- Bowers CY, 1980s
- Research status
- Extensive preclinical; limited clinical
- Study routes
- Subcutaneous, intranasal, oral
- Half-life
- ≈ 30 min
- Key feature
- First-generation GHRP; historical benchmark
Mechanism of Action
GHRP-6 is the prototype GHSR-1a agonist against which later secretagogues are compared. It is a strong GH releaser, but it also engages ghrelin’s appetite pathway strongly and raises prolactin more than the selective peptides — the very properties that motivated the development of Ipamorelin and GHRP-2.
| Component | Detail |
|---|---|
| Primary target | GHSR-1a (ghrelin receptor) |
| G-protein coupling | Gαq/11 → PLC → IP₃ → Ca²⁺ |
| GH release | Strong |
| Prolactin | Significant (highest among these GHRPs) |
| Appetite | Strong (marked ghrelin-mimetic effect) |
Pharmacology
| Parameter | Value |
|---|---|
| Half-life (t½) | ≈ 30 min |
| Bioavailability (SC) | ≈ 70–80% |
| Time to peak (Tmax) | ≈ 15–20 min |
| Metabolism | Proteolytic degradation |
| Route of administration | Subcutaneous, intranasal, oral (research) |
| Elimination | Renal (peptide fragments) |
Research Evidence
Representative studies and their focus are named below; specific numerical outcomes are not restated here as claims.
| Study type | Research focus | Reference |
|---|---|---|
| Foundational pharmacology | First peptide GH secretagogue with oral activity | Bowers CY, et al. |
| Animal / human GH studies | GH release and appetite effects | GHRP-6 literature |
| Cytoprotection research | GHSR signalling beyond GH | GHRP-6 literature |
Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):
| Reported direction / finding | Context | Reference |
|---|---|---|
| First peptide GH secretagogue shown to be orally active | foundational studies | Bowers CY et al. |
| Strong ghrelin-appetite signalling | animal models | GHRP-6 literature |
For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.
Dosing & Reconstitution Reference
Reconstitution and handling parameters for laboratory research. Not dosing guidance for human use.
| Parameter | Reference value |
|---|---|
| Research dose range (literature) | ≈ 100–300 µg per injection, in study protocols |
| Reconstitution solvent | Bacteriostatic water (0.9% benzyl alcohol) |
| Storage (lyophilized) | −20°C, protected from light |
| Storage (reconstituted) | 2–8°C, up to ~2–4 weeks |
| Do not use | If the solution is cloudy or contains particulates |
Safety Profile
Published research observations, provided for reference only. This material is not for human or veterinary use.
| Category | Published observations |
|---|---|
| Local tolerability | Mild injection-site reactions |
| Prolactin / cortisol | Prolactin rise more pronounced than other GHRPs |
| Appetite | Strong |
| Status | For research use only; not for human or veterinary application |
Physicochemical Properties
| Property | Value |
|---|---|
| Physical state | White to off-white lyophilized powder |
| Solubility (water) | Freely soluble |
| logP | ≈ −1.0 (hydrophilic) |
| pH (reconstituted) | 5.0–6.5 |
| Stability (lyophilized) | ≥ 24 months at −20°C |
Synthesis & Manufacturing
GHRP-6 is a C-terminally amidated hexapeptide made by Fmoc solid-phase synthesis, with D-tryptophan and D-phenylalanine as the D-configured residues; the two tryptophans need protection against oxidation at cleavage.
| Step | Detail |
|---|---|
| Strategy | Fmoc solid-phase peptide synthesis |
| Resin | Rink amide resin (C-terminal amide) |
| Special residues | D-Trp, D-Phe (two Trp residues total) |
| Coupling | HBTU / HOBt with DIPEA |
| Cleavage | TFA / TIPS / H₂O with scavengers |
| Purification | Preparative RP-HPLC (C18, TFA/ACN gradient) |
- Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
- Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
- Critical quality attributes: correct molecular weight and low deletion-peptide content. Two tryptophans make it more light-sensitive; confirm the D-residues.
Analytical Methods
| Method | Parameter | Typical result |
|---|---|---|
| RP-HPLC (C18, UV 214 nm) | Purity | ≥ 98% |
| HPLC retention | C18, reversed-phase TFA/ACN gradient | Single main peak |
| ESI-MS (positive mode) | Identity / mass | [M+H]⁺ ≈ 873 Da |
| MALDI-TOF | Mass confirmation | [M+H]⁺ ≈ 873 Da |
| Amino-acid analysis | Composition | Consistent with the stated sequence |
| LC-MS (extracted ion) | Deletion-peptide impurities | Within specification |
| Karl Fischer | Water content | < 6% |
| LAL assay | Endotoxin | Within specification |
| Ion chromatography | Residual TFA | < 500 ppm |
Representative RP-HPLC purity method:
- Column: C18, 5 µm, 250 × 4.6 mm
- Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
- Gradient: reversed-phase TFA/ACN gradient · Flow rate: 1.0 mL/min · Detection: UV 214 nm
- Confirmatory LC-MS: ESI positive mode ([M+H]⁺ ≈ 873 Da). Two tryptophans make it more light-sensitive; confirm the D-residues.
Stability Data
Representative stability behaviour under common storage, handling and formulation conditions.
| Condition | Duration | Result |
|---|---|---|
| Lyophilized, −20°C, dark | ≥ 24 months | No significant degradation (purity > 97%) |
| Lyophilized, 2–8°C, dark | ≥ 12 months | Minimal degradation (purity > 95%) |
| Lyophilized, 25°C (accelerated) | 3 months | < 5% degradation |
| Reconstituted, 2–8°C, dark | 7–14 days | Minor degradation |
| Reconstituted, 25°C | 24–48 h | Use promptly |
| Light exposure (ICH Q1B) | 1.2 M lux·h | Generally light-stable |
| Freeze–thaw (−20°C ⇄ 25°C) | 3 cycles | Acceptable — aliquot to avoid repeats |
- Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
- Minimise freeze-thaw cycles; aliquot material used across many sessions.
- Key factor: Two tryptophans make it more light-sensitive; confirm the D-residues.
Selected References
- Bowers CY, et al. On the in-vitro and in-vivo activity of a new synthetic hexapeptide that acts on the pituitary to release growth hormone. (foundational GHRP literature).
- GHSR-1a / ghrelin-receptor pharmacology reviews.
Quality & Supply
- HPLC ≥ 98% purity with a Certificate of Analysis per batch
- Identity confirmed by LC-MS
- Research samples through to bulk, with worldwide delivery
- Custom quantities and packaging on request
Need GHRP-6 — sample or bulk?
HPLC-verified, COA per batch. Tell us the quantity you need.
